Literature DB >> 19172580

Astragalus membranaceus prevents daunorubicin-induced apoptosis of cultured neonatal cardiomyocytes: role of free radical effect of Astragalus membranaceus on daunorubicin cardiotoxicity.

ZhongGuang Luo1, Lu Zhong, XiaoFeng Han, HaiRong Wang, JiHua Zhong, ZhengHua Xuan.   

Abstract

Anthracyclines are antitumor antibiotics with significant activity against solid and hematologic malignancies. One problem preventing more widespread use has been the development of cardiotoxicity. To determine whether antioxidant agents can reduce the cardiotoxicity of anthracyclines, a herb Astragalus membranaceus was introduced, which has been widely used for the treatment of cardiovascular diseases in China and was confirmed to be an effective antioxidant agent recently. Pre-treatment with Astragalus membranaceus significantly attenuated the daunorubicin-induced increases of reactive oxygen species (p < 0.001), apoptosis (p < 0.05) and the secretions of LDH (p < 0.01) in cultured neonatal cardiomyocytes. Astragalus membranaceus also raised the EC(50) of daunorubicin 1.24-fold. Compared with Astragalus membranaceus, N-acetyl-L-cysteine had similar effects on daunorubicin-induced cell injury, however, superoxide dismutase reduced reactive oxygen species without attenuating apoptosis. The subcellular distribution of DNR was similar to the distribution of MitoTracker Red 580 in mitochondria, which was mainly in the cytoplasm around the nuclear membrane in cultured neonatal cardiomyocytes. In conclusion, the results suggested that Astragalus membranaceus is potentially protective against daunorubicin cardiotoxicity by decreasing free radical release and apoptosis in cultured neonatal cardiomyocytes. The main subcellular distribution of daunorubicin may be in the mitochondria. (c) 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19172580     DOI: 10.1002/ptr.2575

Source DB:  PubMed          Journal:  Phytother Res        ISSN: 0951-418X            Impact factor:   5.878


  7 in total

Review 1.  Insights into the monomers and single drugs of Chinese herbal medicine on myocardial preservation.

Authors:  Shi-Min Yuan; Hua Jing
Journal:  Afr J Tradit Complement Altern Med       Date:  2010-12-30

Review 2.  A systematic review of anticancer effects of radix astragali.

Authors:  Yeehong Jung; Uimin Jerng; Sookyung Lee
Journal:  Chin J Integr Med       Date:  2015-12-07       Impact factor: 1.978

3.  Mitochondrial protection and anti-aging activity of Astragalus polysaccharides and their potential mechanism.

Authors:  Xing-Tai Li; Ya-Kui Zhang; Hai-Xue Kuang; Feng-Xin Jin; De-Wen Liu; Ming-Bo Gao; Ze Liu; Xiao-Juan Xin
Journal:  Int J Mol Sci       Date:  2012-02-07       Impact factor: 6.208

4.  Formononetin, an active compound of Astragalus membranaceus (Fisch) Bunge, inhibits hypoxia-induced retinal neovascularization via the HIF-1α/VEGF signaling pathway.

Authors:  Jianming Wu; Xiao Ke; Na Ma; Wei Wang; Wei Fu; Hongcheng Zhang; Manxi Zhao; Xiaoping Gao; Xiaofeng Hao; Zhirong Zhang
Journal:  Drug Des Devel Ther       Date:  2016-09-23       Impact factor: 4.162

5.  The Extracts and Major Compounds Derived from Astragali Radix Alter Mitochondrial Bioenergetics in Cultured Cardiomyocytes: Comparison of Various Polar Solvents and Compounds.

Authors:  Yun Huang; Kenneth Kin Leung Kwan; Ka Wing Leung; Huaiyou Wang; Xiang Peng Kong; Tina Ting Xia Dong; Karl Wah Keung Tsim
Journal:  Int J Mol Sci       Date:  2018-05-25       Impact factor: 5.923

6.  Halofuginone protects against advanced glycation end products‑induced injury of H9C2 cells via alleviating endoplasmic reticulum stress‑associated apoptosis and inducing autophagy.

Authors:  Yu-Hui Li; Wei-Li Zhang; Hao-Ying Zhou; Da-Wei Yu; Xiao-Ning Sun; Qin Hu
Journal:  Mol Med Rep       Date:  2019-08-06       Impact factor: 2.952

Review 7.  Assessing Drug-Induced Mitochondrial Toxicity in Cardiomyocytes: Implications for Preclinical Cardiac Safety Evaluation.

Authors:  Xiaoli Tang; Zengwu Wang; Shengshou Hu; Bingying Zhou
Journal:  Pharmaceutics       Date:  2022-06-21       Impact factor: 6.525

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.